COVID-19 Disease Burden on the Pediatric Population Grant

Pfizer's competitive grant program aims to support educational initiatives addressing the burden of COVID-19 in the pediatric population, particularly those at high risk. This RFP seeks to enhance the knowledge of healthcare providers, including pediatricians and infectious disease specialists, on identifying and managing severe COVID-19 cases. The program focuses on improving early intervention and understanding COVID-19 complications, ultimately ensuring better outcomes for vulnerable children.

Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Through this RFP it is our intent to support educational programs on the burden of COVID-19 disease in the pediatric patient population with high risk conditions, targeting pediatricians, pediatric infectious disease specialists, and primary care providers who manage high-risk pediatric patients. These programs should aim to equip these providers with the necessary knowledge and skills to identify, diagnose, and manage COVID-19 effectively amongst the pediatric patients at high risk for developing severe COVID-19 outcomes.
Project Types and Area of Interest
Through this RFP it is our intent to support educational programs for HCPs that address knowledge gaps in identifying pediatric patients at high risk for developing severe COVID-19 outcomes, including hospitalization or death, and are designed to help achieve the following goals:
Improve identification of pediatric patients with high-risk conditions and their eligibility for COVID-19 treatment.Recognize the importance of early COVID-19 intervention/treatment in high-risk pediatric patients.Outline COVID-19 complications associated with high-risk conditions and the impact they have on pediatric patients and healthcare systems.
All activity types will be considered and may include educational resources for physicians, for advanced practice providers, or for both, with an emphasis on innovative programs that are designed to meet the needs of a large primary care provider audience.

Eligibility

The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).The project/program lead must be an employee or contractor of the requesting organization.
Requesting organization must be legally able to receive award funding directly from Pfizer Inc. For projects offering continuing education credit, the requesting organization must be accredited.

Ineligibility

Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.